Bristol-Myers Squibb Co. (NYSE:BMY) - Page 2

Top Analyst Upgrades and Downgrades: Amex, Bristol-Myers, Celgene, Cognizant, EA, Fortinet, Lyft, Target, Tilray, Walmart and More

Stocks were indicated to open higher after a strong payrolls report on Friday morning. Despite a pullback this week, the markets remain near all-time highs and investors have solid double-digit ...
Read Full Story »

Big Pharma Scares Off Short Sellers

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

When the stock market is hitting record highs, it's important to remember that it's really a market of stocks rather than a stock market. Not all companies are created equal. ...
Read Full Story »

Unbelievable Swings in Big Pharma Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Major Pharma Sees a Few Wild Swings in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Big Pharma Short Interest Backs Off, With One Huge Exception

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Major Pharma Sees Tremendous Rise in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Major Pharma Scares Off Short Sellers

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Reality Check: Big Biotech and Big Pharma Are Becoming Identical

There is great opportunity in healthcare. There is also quite a lot of risk. Politicians and consumers alike want lower drug prices. Patients want the best of the best options ...
Read Full Story »

Short Interest Spikes in a Couple Major Pharma Stocks

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

The 6 Most Shorted NYSE Stocks

After one of the most brutal Decembers for stock investors in many years, we turned the calendar page on a new year. While the volatility did not go away, the ...
Read Full Story »

Why the Bristol-Myers Incredible Earnings Beat Is Getting Grounded

When Bristol-Myers Squibb Co. (NYSE: BMY) reported its most recent quarterly results before the markets opened on Thursday, the company said that it had $0.94 in earnings per share (EPS) ...
Read Full Story »

Major Pharma Sees Fading Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Thursday’s Biggest Winners and Losers in the S&P 500

January 3, 2019: The S&P 500 closed down 2.5% at 2,447.96. The DJIA closed down 2.8% at 22,686.36. Separately, the Nasdaq closed down 3.0% at 6,463.50. Thursday was a down ...
Read Full Story »

Apple, Bristol-Myers Plummet into Thursday’s 52-Week Low Club

January 3, 2019: Here are four stocks trading with heavy volume among 66 equities trading at new 52-week lows shortly before Thursday's closing bell. On the NYSE, decliners led advancers ...
Read Full Story »